AstraZeneca and Bristol-Myers Squibb in Merger Talks Valued at Nearly $400 Billion
Claire Weston
AstraZeneca is in merger talks with Bristol Myers Squibb, the Financial Times reports, with the combined entity valued at nearly $400 billion — a deal that would rank among the largest pharma mergers in history and accelerate AstraZeneca's strategic pivot toward the U.S. market.
How big is this deal?
AstraZeneca's current market cap is roughly £196 billion, making it Britain's second-largest listed company. Bristol Myers Squibb is valued at about $133 billion.
The combined entity would be worth close to $400 billion, placing it among the largest M&A transactions ever.
This means → this is not one company swallowing another — it is a merger of equals between two hundred-billion-dollar giants, large enough to reshape global pharma competition.
How far along are the talks?
People familiar with the matter say the two sides have held multiple rounds of discussions over recent months and could reach a deal soon.
However, talks could still be delayed or collapse entirely. AstraZeneca declined to comment; Bristol Myers Squibb did not immediately respond.
In plain terms = several rounds in, real momentum — but nothing is signed, and it could fall apart at any point.
Why does AstraZeneca want this?
The deal is driven by AstraZeneca CEO Pascal Soriot as a major strategic move to shift the company's center of gravity toward the U.S. market.
AstraZeneca already elevated its New York listing status in June this year — a step widely seen as a blow to the London Stock Exchange.
This reflects a broader trend: large global pharma companies are racing toward the U.S., the world's single biggest drug market. Merging with Bristol Myers Squibb would give AstraZeneca an instant foothold — U.S. pipelines, sales networks, and market presence in one move.
Content is for reference only, not financial advice.